ADAPTABLE – The Aspirin Study
| March 2017 – The Sheps Center is partnering with the School of Medicine and TraCS to recruit patients for a pragmatic clinical trial comparing low dose (81mg) aspirin to regular strength (325mg) aspirin among patients with known heart disease. We are recruiting UNC HealthCare patients across the state. UNC is one of nearly 30 sites across the US enrolling patients.
Patients who meet the inclusion criteria are invited to participate via letter, email, MyChart message, and/or face-to-face in a UNC clinic. Participation includes taking a daily dose of aspirin and completing surveys online every 3-6 months for up to three years. Darren DeWalt, MD, MPH, is the principal investigator at UNC. For more information about ADAPTABLE at UNC, see the links to the right or call 919-966-9484.
WHY IS THIS STUDY BEING DONE?For more than 40 years, doctors have been telling patients with heart disease to take aspirin. For these patients, taking aspirin every day can lower the risk of heart attacks and strokes. Millions of Americans who have heart disease already take either regular (325 mg) or low-dose (81 mg) aspirin. Many studies have shown that both doses work and both are generally safe. The most common side effect of aspirin is an upset stomach. Aspirin can also make you bleed more easily. In rare cases (about 5 in 1,000 people), it can cause dangerous bleeding in the stomach, brain, or other places. Even though both doses of aspirin are widely used, no one knows which is better. Regular aspirin has a higher risk of bleeding than low-dose aspirin. But no one knows if low-dose aspirin is both safer and works just as well as regular aspirin to prevent heart and blood vessel problems. The goal of ADAPTABLE is to try to find out which dose of aspirin is better for patients like you who have heart disease. Patients who join this study will take either low-dose or regular aspirin every day. That way, we can learn which is better in terms of reducing the risk of heart attacks, strokes, bleeding, and death. We expect 20,000 patients with heart disease from across the US will take part in ADAPTABLE.
WHO IS DOING THIS STUDY?The Patient-Centered Outcomes Research Institute (PCORI) is funding this study. The Duke Clinical Research Institute (DCRI) is leading the study, which will be carried out by the Patient-Centered Outcomes Research Network (PCORnet). PCORnet is a unique partnership among patients, clinicians, and health systems. Their goal is to change how research is done so that the focus on research is on the needs of patients. |
|
You must be logged in to post a comment.